NasdaqGS - Delayed Quote • USD
Adaptive Biotechnologies Corporation (ADPT)
At close: April 24 at 4:00 PM EDT
Pre-Market: 8:21 AM EDT
Earnings Estimate
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
No. of Analysts | 7 | 7 | 7 | 7 |
Avg. Estimate | -0.34 | -0.33 | -1.3 | -1.04 |
Low Estimate | -0.37 | -0.34 | -1.37 | -1.29 |
High Estimate | -0.31 | -0.31 | -1.21 | -0.65 |
Year Ago EPS | -0.4 | -0.33 | -1.56 | -1.3 |
Revenue Estimate
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
No. of Analysts | 7 | 7 | 8 | 8 |
Avg. Estimate | 38.78M | 43.36M | 175.82M | 220.94M |
Low Estimate | 34.8M | 41.66M | 170M | 195.5M |
High Estimate | 42.2M | 46.4M | 185.1M | 256.4M |
Year Ago Sales | 37.65M | -- | 170.28M | 175.82M |
Sales Growth (year/est) | 3.00% | -- | 3.30% | 25.70% |
Earnings History
CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
---|---|---|---|---|
EPS Est. | -0.38 | -0.35 | -0.34 | -0.33 |
EPS Actual | -0.4 | -0.33 | -0.35 | -0.48 |
Difference | -0.02 | 0.02 | -0.01 | -0.15 |
Surprise % | -5.30% | 5.70% | -2.90% | -45.50% |
EPS Trend
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
Current Estimate | -0.34 | -0.33 | -1.3 | -1.04 |
7 Days Ago | -0.34 | -0.33 | -1.3 | -1.04 |
30 Days Ago | -0.35 | -0.33 | -1.31 | -1.06 |
60 Days Ago | -0.35 | -0.33 | -1.31 | -1.06 |
90 Days Ago | -0.32 | -0.31 | -1.13 | -0.83 |
EPS Revisions
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
Up Last 7 Days | -- | -- | -- | -- |
Up Last 30 Days | 1 | -- | 1 | -- |
Down Last 7 Days | -- | -- | -- | -- |
Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
CURRENCY IN USD | ADPT | Industry | Sector | S&P 500 |
---|---|---|---|---|
Current Qtr. | 15.00% | -- | -- | 1.50% |
Next Qtr. | 0.00% | -- | -- | 11.40% |
Current Year | 16.70% | -- | -- | 5.20% |
Next Year | 20.00% | -- | -- | 13.40% |
Next 5 Years (per annum) | 21.60% | -- | -- | 11.09% |
Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
Maintains | BTIG: Buy to Buy | 4/4/2024 |
Maintains | Goldman Sachs: Neutral to Neutral | 2/16/2024 |
Maintains | JP Morgan: Overweight to Overweight | 2/15/2024 |
Maintains | Piper Sandler: Overweight to Overweight | 11/13/2023 |
Maintains | Morgan Stanley: Equal-Weight to Equal-Weight | 10/24/2023 |
Maintains | Piper Sandler: Overweight to Overweight | 10/16/2023 |
Related Tickers
FATE Fate Therapeutics, Inc.
4.3000
-5.29%
ADAP Adaptimmune Therapeutics plc
1.0800
-5.26%
ALLO Allogene Therapeutics, Inc.
3.0400
-9.79%
ABCL AbCellera Biologics Inc.
3.9000
-1.76%
EDIT Editas Medicine, Inc.
5.35
-2.01%
BEAM Beam Therapeutics Inc.
22.74
-3.11%
NTLA Intellia Therapeutics, Inc.
21.17
-1.67%
ADCT ADC Therapeutics SA
4.7800
-3.82%
AMLX Amylyx Pharmaceuticals, Inc.
1.8800
-3.59%
RPTX Repare Therapeutics Inc.
3.3000
-1.79%